Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab for adults with hypereosinophilic syndrome
CTR20222121Phase 3Active
- Sponsor
- GSK
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of depemokimab in hypereosinophilic syndrome (HES), sponsored by GSK. Primary endpoint: Frequency of HES flares during the 52-week treatment period. Started Nov 2022; status: active.
02
Drugs
depemokimab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on CTR20222121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222121.